Picture of Charles River Laboratories International logo

CRL Charles River Laboratories International Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m+9.87%
3m+5.26%
6m+13.15%
1yr+6.75%
Volume Change (%)
10d/3m-9.49%
Price vs... (%)
52w High-0.88%
50d MA+14.19%
200d MA+28.79%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)24.07
PEG Ratio (f)1.01
EPS Growth (f)31.27%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.89
Price to Tang. Bookn/a
Price to Free Cashflow38.31
Price to Sales3.39
EV to EBITDA15.58

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital10.37%
Return on Equity15.25%
Operating Margin17.94%

Financial Summary

Year End 30th DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue$m2,621.232,923.933,540.163,976.064,129.414,220.734,531.5912.75%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+16.47+33.54+4.58+16.62-14.9+38.93+12.81n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Dec 202430th Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Charles River Laboratories International EPS forecast chart

Profile Summary

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Directors

Last Annual
December 30th, 2023
Last Interim
December 30th, 2023
Incorporated
February 3rd, 1994
Public Since
June 23rd, 2000
No. of Shareholders
67
No. of Employees
20,000
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNew York Stock Exchange
Shares in Issue
51,349,770
Blurred out image of a map
Address
251 Ballardvale St, WILMINGTON, 01887
Web
https://www.criver.com/
Phone
+1 7812226000
Auditors
PricewaterhouseCoopers LLP

CRL Share Price Performance

Upcoming Events for CRL

Charles River Laboratories International Inc Annual Shareholders Meeting

Q1 2024 Charles River Laboratories International Inc Earnings Release

Q2 2024 Charles River Laboratories International Inc Earnings Release

Similar to CRL

Picture of ADC Therapeutics SA logo

ADC Therapeutics SA

us flag iconNew York Stock Exchange

Picture of Alto Neuroscience logo

Alto Neuroscience

us flag iconNew York Stock Exchange

Picture of Annovis Bio logo

Annovis Bio

us flag iconNew York Stock Exchange

Picture of Arcus Biosciences logo

Arcus Biosciences

us flag iconNew York Stock Exchange

Picture of Biohaven logo

Biohaven

us flag iconNew York Stock Exchange

FAQ